Teva Pharmaceutical Industries did not meet the primary endpoint of its Phase II trial to evaluate the efficacy, safety and tolerability of Talampanel, a drug that reduces disease-related functional deterioration in amyotrophic lateral sclerosis (ALS) patients.
The study results indicate the drug is safe but did not meet the efficacy requirements.
Go deeper with GlobalData
The double-blind, multicentre, multinational, randomised study was conducted in 25 sites across Canada, Israel, Europe and the US, involving 559 patients with ALS.
Also known as Lou Gehrig’s disease, ALS is a degenerative motor neuron disease that leads to paralysis and ultimately death within five years from the disease’s onset.
Over 10,000 patients every year are diagnosed with ALS in Europe and the US.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
